Cardiology Product Guide » coronary stent http://blog.cardiologyproductguide.com A comprehensive guide to cardiology products for medical professionals Tue, 14 Jun 2011 11:39:11 +0000 en hourly 1 http://wordpress.org/?v=3.1.3 Clinical Trial Enrollment For SYNERGY(TM) Coronary Stent With Bioabsorbable Polymer And Everolimus Drug Coating EVOLVE http://blog.cardiologyproductguide.com/2010/09/07/clinical-trial-enrollment-for-synergytm-coronary-stent-with-bioabsorbable-polymer-and-everolimus-drug-coating-evolve/ http://blog.cardiologyproductguide.com/2010/09/07/clinical-trial-enrollment-for-synergytm-coronary-stent-with-bioabsorbable-polymer-and-everolimus-drug-coating-evolve/#comments Tue, 07 Sep 2010 07:43:02 +0000 admin http://www.cardiologyproductguide.com/blog/?p=399 Boston Scientific CorporationBoston Scientific Corporation has announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY™ Coronary Stent. The SYNERGY Stent uses a bioabsorbable PLGA polymer and everolimus drug formulation to create a thin, uniform coating confined to the outer surface of the stent. Once the drug has been delivered, the bioabsorbable coating resorbs into the body, leaving behind only a bare-metal stent.

Read the full story here

]]> http://blog.cardiologyproductguide.com/2010/09/07/clinical-trial-enrollment-for-synergytm-coronary-stent-with-bioabsorbable-polymer-and-everolimus-drug-coating-evolve/feed/ 0 Boston Scientific Begins Clinical Trial Enrollment For New Coronary Stent With Bioabsorbable Polymer And Everolimus Drug Coating http://blog.cardiologyproductguide.com/2010/08/17/boston-scientific-begins-clinical-trial-enrollment-for-new-coronary-stent-with-bioabsorbable-polymer-and-everolimus-drug-coating/ http://blog.cardiologyproductguide.com/2010/08/17/boston-scientific-begins-clinical-trial-enrollment-for-new-coronary-stent-with-bioabsorbable-polymer-and-everolimus-drug-coating/#comments Tue, 17 Aug 2010 08:14:31 +0000 admin http://www.cardiologyproductguide.com/blog/?p=379 Boston Scientific CorporationBoston Scientific Corporation has announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY™ Coronary Stent. The SYNERGY Stent uses a bioabsorbable PLGA polymer and everolimus drug formulation to create a thin, uniform coating confined to the outer surface of the stent. Once the drug has been delivered, the bioabsorbable coating resorbs into the body, leaving behind only a bare-metal stent.

Read the full story here

]]> http://blog.cardiologyproductguide.com/2010/08/17/boston-scientific-begins-clinical-trial-enrollment-for-new-coronary-stent-with-bioabsorbable-polymer-and-everolimus-drug-coating/feed/ 0 Boston receives FDA approval for Taxus Liberte http://blog.cardiologyproductguide.com/2009/07/21/boston-receives-fda-approval-for-taxus-liberte/ http://blog.cardiologyproductguide.com/2009/07/21/boston-receives-fda-approval-for-taxus-liberte/#comments Tue, 21 Jul 2009 18:20:41 +0000 admin http://www.cardiologyproductguide.com/blog/2009/07/21/boston-receives-fda-approval-for-taxus-liberte/ Boston Scientific has received the FDA approval to market its Taxus Liberte long paclitaxel-eluting coronary stent system, a next-generation drug-eluting stent designed for long lesions. At 38mm, Taxus Liberte long stent is the longest available drug-eluting stent (DES). This provides doctors with an option that can potentially reduce the number of stents used in more complex cases, simplifying procedures and reducing costs. The company plans to launch the product in the US in August.

]]> http://blog.cardiologyproductguide.com/2009/07/21/boston-receives-fda-approval-for-taxus-liberte/feed/ 0 MGuard coronary stent trial depicts positive efficacy and safety data http://blog.cardiologyproductguide.com/2008/06/26/mguard-coronary-stent-trial-depicts-positive-efficacy-and-safety-data/ http://blog.cardiologyproductguide.com/2008/06/26/mguard-coronary-stent-trial-depicts-positive-efficacy-and-safety-data/#comments Thu, 26 Jun 2008 20:21:25 +0000 admin http://www.cardiologyproductguide.com/blog/2008/06/26/mguard-coronary-stent-trial-depicts-positive-efficacy-and-safety-data/ InspireMDInspireMD has achieved positive results with its MGuard coronary stent in an ongoing multicenter trial aimed at establishing the safety and efficacy of the product in high-risk patients with complex lesions. The study’s six-month data demonstrates no thrombosis and an overall MACE rate of 6.6%. The data also highlight the efficacy of MGuard in maintaining blood flow through the treated vessel after six months, according to the company. The product, which combines a coronary stent with an embolic protection device, has received a CE Marking to treat patients with coronary artery diseases.

]]> http://blog.cardiologyproductguide.com/2008/06/26/mguard-coronary-stent-trial-depicts-positive-efficacy-and-safety-data/feed/ 0